AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)

Phase 4

Completed

Conditions: Gastroesophageal Reflux Disease

Interventions: Drug: Esomeprazole 40 mg
Procedure: Physical Exam
Other: Quality of Life Questionnaires
Procedure: pregnancy test, if applicable

First Posted Date: 2008-08-13

Last Posted Date: 2012-10-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 314

Registration Number: NCT00734097

Locations: 🇻🇪
Research Site, San Cristobal, Venezuela

Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: AZD6140

First Posted Date: 2008-08-13

Last Posted Date: 2010-12-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 24

Registration Number: NCT00733265

Locations: 🇺🇸
Research Site, San Antonio, Texas, United States

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918

Phase 1

Terminated

Conditions: Cancer,
Solid Tumors
Advanced Solid Malignancies

Interventions: Drug: AZD6918
Drug: gemcitabine
Drug: pemetrexed

First Posted Date: 2008-08-12

Last Posted Date: 2010-12-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 75

Registration Number: NCT00733031

Locations: 🇺🇸
Research Site, Nashville, Tennessee, United States

Depiction of Prostate Cancer Treatment Alternatives in Greece

Completed

Conditions: Locally Advanced or Metastatic Prostate Cancer.

First Posted Date: 2008-08-12

Last Posted Date: 2009-10-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 310

Registration Number: NCT00733213

Locations: 🇬🇷
Research Site, Xsanthi, Greece

A Study of Tor Kinase Inhibitor in Advanced Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: AZD8055

First Posted Date: 2008-08-08

Last Posted Date: 2012-07-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 64

Registration Number: NCT00731263

Locations: 🇬🇧
Research Site, Sutton, Surrey, United Kingdom

Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: AZD3241
Drug: Placebo

First Posted Date: 2008-08-07

Last Posted Date: 2008-11-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 64

Registration Number: NCT00729443

Locations: 🇸🇪
Research Site, Stockholm, Sweden

Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: exenatide
Drug: sitagliptin
Drug: placebo

First Posted Date: 2008-08-07

Last Posted Date: 2015-04-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 83

Registration Number: NCT00729326

Locations: 🇺🇸
Research Site, San Antonio, Texas, United States

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.

Phase 1

Completed

Conditions: Adverse Events
Pharmacokinetic Variables

Interventions: Drug: ABT-143
Drug: ABT-335 and rosuvastatin

First Posted Date: 2008-08-06

Last Posted Date: 2012-09-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 32

Registration Number: NCT00728780

Locations: 🇺🇸
Site Reference ID/Investigator# 11101, Evansville, Indiana, United States

Retrospective Observational Trial on Reasons for Withdraw of Adjuvant Tamoxifen in Breast Cancer Patients

Completed

Conditions: Breast Cancer

First Posted Date: 2008-08-04

Last Posted Date: 2010-12-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 190

Registration Number: NCT00727883

Renal Mechanism of Action/Splay vs. TmG

Phase 1

Terminated

Conditions: Diabetes, NOS

Interventions: Drug: Dapagliflozin

First Posted Date: 2008-08-01

Last Posted Date: 2016-10-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 1

Registration Number: NCT00726505

Locations: 🇺🇸
University Of Texas Health Center At San Antonio, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy